• 1
    Aristotle. Meta ta Fusika. Athens , Greece : Kaktos; 1993. (Transl. Kostis JB).
  • 2
    Wang J-G, Staessen JA. Benefits of antihypertensive pharmacologic therapy and blood pressure reduction in outcomes trials. 2003;5(1):6675.
  • 3
    Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet. 2000;356:19491954.
  • 4
    Blood Pressure Lowering Treatment Trialists' collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet. 2000;355:19551964.
  • 5
    Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597603.
  • 6
    Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular events in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645652.
  • 7
    Kostis JB. The effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular dysfunction. Am J Hypertens. 1995;8:909914.
  • 8
    Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285(21): 27192728.
  • 9
    The Joint National Committee on Prevention Detection Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med. 1997;157:24132446.
  • 10
    Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens. 1999;17: 151183.
  • 11
    Moser M, Pickering TG, Weber MA. Roundtable discussion: blood pressure lowering by any means, or do specific medications make a difference? J Clin Hypertens. 2001;3(6):369375.
  • 12
    Moser M. Is it time for a new approach to the initial treatment of hypertension? Arch Intern Med. 2001;161(9):11401144.
  • 13
    Hansson L, Lindholm LH, Ekbom T, et al., for the STOP-Hypertension-2 study group. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:17511756.
  • 14
    Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359(9311):10041010.